Coherus

 – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the…

Exton, Pennsylvania, June 23, 2023 (GLOBE NEWSWIRE) -- Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars Today and Tomorrow (US) series since Q4…

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in the US; if approved, toripalimab will…

<!-- Name:DistributionId Value:8747614 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections…

– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression – …

– CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer –– UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million –– 2022 R&D and SG&A expense guidance reduced…

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…

REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today…

SHANGHAI, China and REDWOOD CITY, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United…